Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis

Table 1 Biographical and clinical characteristics of the patients studied (intent-to-treat population¹)

Patients (ITT analysis)	n = 35
Age: median/range (yr)	35 (20-72)
Female n (%)	10 (28.6)
Smoker n (%)	2 (5.7)
Ex-smoker n (%)	19 (54.3)
Disease: duration (mean+SE, yr) 7.2+0.8
Site of disease: extent n (%):
Proctosigmoiditis	3 (8.6)
Left sided	9 (25.7)
Pancolitis	23 (65.7)
Pretreatment (all patients had steroids)
Aminosalicylates n (%)	25 (74.40%)
Immunosuppressants n (%)	13 (37.10%)

¹Note: Per-protocol population comprised all but one ITT patient.